Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H30ClFN2O3 |
| Molecular Weight | 521.022 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H]([C@@H](C1=CNC2=C(F)C=C(C)C=C12)C3=CC=C(Cl)C=C3)C4=CC=C(C=C4)C(=O)NCCC(O)=O
InChI
InChIKey=FYRJJCYFYLLOSC-LXFBAYGMSA-N
InChI=1S/C30H30ClFN2O3/c1-3-4-23(19-5-7-21(8-6-19)30(37)33-14-13-27(35)36)28(20-9-11-22(31)12-10-20)25-17-34-29-24(25)15-18(2)16-26(29)32/h5-12,15-17,23,28,34H,3-4,13-14H2,1-2H3,(H,33,37)(H,35,36)/t23-,28+/m1/s1
| Molecular Formula | C30H30ClFN2O3 |
| Molecular Weight | 521.022 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
MK 3577 is an orally active glucagon receptor antagonist which was under development by Merck & Co for the treatment of type 2 diabetes mellitus. MK 3577 demonstrate activity in cellular models and preclinical trials. In phase II clinical trials MK 3577 shows good efficacy and acceptable level of adverse events, but no further development reports were published.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:42:29 GMT 2023
by
admin
on
Sat Dec 16 11:42:29 GMT 2023
|
| Record UNII |
03TW1410NL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
46240797
Created by
admin on Sat Dec 16 11:42:29 GMT 2023 , Edited by admin on Sat Dec 16 11:42:29 GMT 2023
|
PRIMARY | |||
|
DB14957
Created by
admin on Sat Dec 16 11:42:29 GMT 2023 , Edited by admin on Sat Dec 16 11:42:29 GMT 2023
|
PRIMARY | |||
|
03TW1410NL
Created by
admin on Sat Dec 16 11:42:29 GMT 2023 , Edited by admin on Sat Dec 16 11:42:29 GMT 2023
|
PRIMARY | |||
|
1019112-29-8
Created by
admin on Sat Dec 16 11:42:29 GMT 2023 , Edited by admin on Sat Dec 16 11:42:29 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
More complete GCGr blockade led to better glycemic control, but also LDL-C increases, whereas partial GCGr blockade led to smaller effects on glycemic control and LDL-C.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Purpose: This study will assess the safety and efficacy of MK3577 when given in the morning, the evening, or twice a day as compared to placebo and to metformin.
|
||
|
ACTIVE MOIETY |
Originator: Merck & Co; Class: Anti-hyper-glycaemic; Mechanism of Action: Glucagon receptor antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Discontinued for Type 2 diabetes mellitus; Most Recent Event: 08 Mar 2010 MK 3577 is still in phase II development
|
